Reverse transcriptase inhibitors in HIV/AIDS therapy
Author(s)
Bibliographic Information
Reverse transcriptase inhibitors in HIV/AIDS therapy
(Infectious disease)
Humana Press, c2006
Available at / 1 libraries
-
No Libraries matched.
- Remove all filters.
Note
foreword by Joep M.A. Lange
Includes bibliographical references and index
Contents of Works
- Structural studies on HIV reverse transcriptase related to drug discovery / David K. Stammers and Jingshan Ren
- Zidovudine, lamivudine, and abacavir / Monica Carten and Harold Kessler
- Stavudine, didanosine, and zalcitabine / Gail Skowron, Sapna Chowdhry and Michael R. Stevens
- Emtricitabine / Gail Skowron, Jeffrey Bratberg and Rudi Pauwels
- Nucleotide analogs / Craig J. Hoesley
- Resistance to nucleoside and nucleotide reverse transcriptase inhibitors / Nancy Shulman and Mark Winters
- Pharmacokinetics of reverse transcriptase inhibitors / Patrick Hoggard ... [et al.]
- Peripheral neuropathy associated with nucleoside reverse transcriptase inhibitor therapy / Bruce A. Cohen and Russell Bartt
- Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: a pathophysiological perspective / William Lewis
- Mitochondrial toxicity and lipodystrophy / Grace McComsey
- Nevirapine / David Asmuth and Richard Pollard
- Efavirenz / Graeme J. Moyle and Brian Conway
- Delavirdine / Brian Conway
- Resistance to non-nucleoside reverse transcriptase inhibitors / F. Ramzi Asfour and Richard Haubrich
- Vertical transmission of HIV and therapeutic interventions / Susan Cu-Uvin, Arlene Bardeguez and Carla Chibwesha
- New reverse transcriptase inhibitors in development / Rudi Pauwels
- Antiretroviral drugs for millions / Allan Ronald, Ellie Katabira and Merle Sande
Description and Table of Contents
Description
A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.
Table of Contents
Structural Studies on HIV Reverse Transcriptase Related to Drug Discovery
David K. Stammers and Jingshan Ren
Zidovudine, Lamivudine, and Abacavir
Monica Carten and Harold Kessler
Stavudine, Didanosine, and Zalcitabine
Gail Skowron, Sapna Chowdhry, and Michael R. Stevens
Emtricitabine
Gail Skowron, Jeffrey Bratberg, and Rudi Pauwels
Nucleotide Analogs
Craig J. Hoesley
Resistance to Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Nancy Shulman and Mark Winters
Pharmacokinetics of Reverse Transcriptase Inhibitors
Patrick Hoggard, Stephen Kewn, Saye Khoo and David Back
Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy
Bruce A. Cohen and Russell Bartt
Mitochondrial Dysfunction and Nucleoside Reverse Transcriptase Inhibitor Therapy: A Pathophysiological Perspective
William Lewis
Mitochondrial Toxicity and Lipodystrophy
Grace McComsey
Nevirapine
David Asmuth and Richard Pollard
Efavirenz
Graeme J. Moyle and Brian Conway
Delavirdine
Brian Conway
Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
F. Ramzi Asfour and Richard Haubrich
Vertical Transmission of HIV and Therapeutic Interventions
Susan Cu-Uvin, Arlene Bardeguez, and Carla Chibwesha
New Reverse Transcriptase Inhibitors in Development
Rudi Pauwels
Antiretroviral Drugs for Millions
Allan Ronald, Elly Katabira, and Merle Sande
Postscript
Richard Ogden and Gail Skowron
Index
by "Nielsen BookData"